TherapeuticsMD (TXMD) Cash from Investing Activities Growth (3y) (2014 - 2022)
Powered by 
Analysis
TherapeuticsMD (TXMD) Cash from Investing Activities Growth (3y) (2014 - 2022) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 33.51% |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | -51.98% |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 21.19% |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | -47.89% |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 27.70% |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | -69.92% |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | - |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | -39.73% |
| 10 | TherapeuticsMD | 25.35 Mn | 16.16 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 84.71% |
| Sep 30, 2022 | 26.10% |
| Jun 30, 2022 | 60.25% |
| Mar 31, 2022 | 31.72% |
| Dec 31, 2021 | -31.15% |
| Sep 30, 2021 | 79.24% |
| Jun 30, 2021 | 34.13% |
| Mar 31, 2021 | -34.37% |
| Dec 31, 2020 | -12.01% |
| Sep 30, 2020 | -53.69% |
| Jun 30, 2020 | -14.17% |
| Mar 31, 2020 | -48.48% |
| Dec 31, 2019 | -275.25% |
| Sep 30, 2019 | -86.63% |
| Jun 30, 2019 | -34.44% |
| Mar 31, 2019 | -59.21% |
| Dec 31, 2018 | -14.19% |
| Sep 30, 2018 | -703.50% |
| Jun 30, 2018 | -75.60% |
| Mar 31, 2018 | -69.83% |